Cook Medical named Rob Lyles executive vice president, the latest move in a larger management shift at the Indiana medtech maker.
Lyles was formerly vice president of Cook’s peripheral intervention division. He has been with the company since 2003 and was named division VP in 2007. Lyles’ promotion follows the advancement of Pete Yonkman to president of the Cook Medical. Mark Breedlove, a 19-year veteran of Cook Medical, will succeed Lyles as VP of the peripheral intervention division.
"The PI team has been responsible for numerous breakthroughs in patient care from embolization coils to vena cava filters to drug-eluting stents. Rob has played an important role in that exciting era at Cook, and in his new role, he will be leading our strategic efforts to explore a range of new technologies that promise to enhance patient care just as much," president Pete Yonkman said in prepared remarks.
NuVasive adds Life Tech CEO to board
NuVasive Inc. (NSDQ:NUVA) said it named Gregory Lucier to its board of directors. Lucier is chairman and CEO of Life Technologies (NSDQ:LIFE), which was recently bought out by Thermo Fisher (NYSE:TMO). He is also on the board for CareFusion (NYSE:CFN) and Synthetic Genomics.
Read more
Stryker appoints IDEX Corp. CEO to board
Stryker (NYSE:SYK) said it named Andrew Silvernail to its board of directors. Silvernail is the CEO of IDEX Corporation, a company that specializes in the development, design, and manufacture of fluidics systems and specialty engineered products.
Read more
Orthofix names new director
Orthofix (NSDQ:OFIX) added Dr. Anthony Martin to its board of directors. Martin is also the non-executive Chairman of Immunodiagnostics Systems Holdings plc, Sphere Medical Holding plc, and Phico Therapeutics Ltd.
Read more
InspireMD nabs Covidien exec. sales VP
InspireMD (OTC:NSPR) appointed Rick Olson as vice president of global sales operations. Olson was previously director of international strategy and high performance management systems at Covidien (NYSE:COV) and held leadership roles within Boston Scientific (NYSE:BSX).
Read more
